Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Emerging Treatments and Technologies

Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes

First two cases

  1. Riccardo Calafiore, MD1,
  2. Giuseppe Basta, MD1,
  3. Giovanni Luca, MD1,
  4. Angelo Lemmi, MD2,
  5. M. Pia Montanucci, PHD1,
  6. Giuseppe Calabrese, MD1,
  7. Leda Racanicchi, PHD1,
  8. Francesca Mancuso, PHD1 and
  9. Paolo Brunetti, MD1
  1. 1Department of Internal Medicine, University of Perugia, Perugia, Italy
  2. 2Department of Radiology and Imaging, University of Perugia, Perugia, Italy
  1. Address correspondence and reprint requests to Riccardo Calafiore, MD, Department of Internal Medicine, University of Perugia, Via E. Dal Pozzo, 06126 Perugia, Italy. E-mail: islet{at}unipg.it
Diabetes Care 2006 Jan; 29(1): 137-138. https://doi.org/10.2337/diacare.29.01.06.dc05-1270
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading
  • OGTT, oral glucose tolerance test
  • sCPR, serum C-peptide response
  • TX, human islet allograft

Time-related decline of human islet allograft (TX) function in generally immunosuppressed type 1 diabetic patients (1–5) has led us, after years of preclinical study (6), to initiate a phase 1 pilot clinical trial of microencapsulated TX into 10 nonimmunosuppressed patients with type 1 diabetes, under permission and surveillance by the Italian Ministry of Health (file no. 19382, PRE 805, 5 September 2003).

RESEARCH DESIGN AND METHODS

Human islet procurement

Human islets were isolated from single-donor pancreases according to the Edmonton protocol (1). Only preparations complying with standard quality control criteria (1) were considered for TX. The islets were cultured for 24 h in HAM F12 (Celbio, Milano, Italy), supplemented with antibiotics and 1.25% human albumin (Kedrion Spa, Milano, Italy) at 37°C in 95% air/CO2.

Microencapsulation

The islets were washed and thoroughly mixed with 1.6% endotoxin- and pyrogen-free sodium alginate (Stern Italia, Milan, Italy) that had been highly purified according to U.S. Pharmacopeia. Upon extrusion through a microdroplet generator (droplets generated by combination of air shears and mechanical pressure by a peristaltic pump), microdroplets containing the islets, upon collection in a CaCl2 bath, turned into gel microbeads. The beads, containing 1–2 islets and measuring an average 500 μm in diameter, were sequentially double-coated with 0.12% and 0.06% poly-l-ornithine (Sigma) and finally with 0.04% sodium alginate (Stern) (7).

Patient recruitment

Ten patients with long-standing type 1 diabetes on intensive insulin therapy regimens (lispro prebreakfast, lunch, and supper and glargine presupper) and undetectable serum C-peptide responses (sCPRs) were tested for complete blood chemistry, parameters of diabetes control (GHb, daily blood glucose profiles, and insulin requirement), anti–GAD 65 antibodies, and islet cell antibodies. Chest X-ray and abdominal echography were also performed.

Pre- and post-TX patient assessment

The patients were maintained on euglycemia overnight before TX by supplementing exogenous insulin as required. After TX, the patients were monitored hourly for blood glucose (range: 80–150 mg/dl) and insulin requirement. sCPR samples, assayed by radioimmunoassay (sCPR sensitivity: 0.06 ng/ml [intra-assay CV 3.7–4.5%, interassay CV 4.4–5%]) (TechnoGenetics, Milan, Italy) in our laboratory, were drawn twice daily for the first 7 days and weekly thereafter, both in basal and 90 min after meals. A 75-g oral glucose tolerance test (OGTT) was scheduled for patient 1 at 60 days post-TX. At 7 days post-TX, the patients were discharged and instructed to continue blood glucose home self-monitoring, with adjustments of insulin requirement. At 30 days post-TX, control abdominal echography was scheduled.

Encapsulated human islets for TX

A total of 400,000 and 600,000 microencapsulated islets (islet equivalents normalized to 150 μ) were grafted in patient 1 and patient 2, respectively. The final TX volume included 50 ml of microcapsules diluted in 100 ml of saline. Empty microcapsules did not exceed 5% of total.

Site of TX and delivery procedure.

At the Department of Radiology and Imaging, with the patients under local anesthesia (2% xylocaine) but no systemic sedation, the central abdominal region, under echography guidance, was punctured by a 14-gauge needle and therein injected with a few milliliters of saline to create a virtual space within the peritoneal leaflets for microcapsule delivery by a 60- ml plastic syringe over 15 min.

RESULTS

Both patients showed a rise in sCPR levels several weeks post-TX, amelioration of their mean daily blood glucose levels, and a progressive decline in exogenous insulin consumption. GHb also decreased throughout months of post-TX follow-up. At 60 days post-TX, an OGTT in patient 1 showed a biphasic C-peptide response, compatible with the presence of differentiated islet β-cells. At 1 year (patient 1) and 6 months (patient 2) of post-TX follow-up, which is in progress, sCPR was still detected in these recipients (Table 1).

View this table:
  • View inline
  • View popup
Table 1—

Patients 1 and 2 pre- and post-TX

CONCLUSIONS

Our long-standing experimental background in the field has enabled us to initiate a pilot clinical trial of microencapsulated human islet TX into nonimmunosuppressed patients with type 1 diabetes. Current data seems to show that the TX procedure is simple, noninvasive, painless, and devoid of side effects. Although the patients were unable, thus far, to withdraw exogenous insulin, we believe that decline in GHb, disappearance (patient 1) of frequent weekly hypoglycemic episodes, and responsiveness to OGTT (patient 1) overall indicated TX metabolic function. Adjustments in grafted viable islet cell mass dosing might further improve clinical results in the remaining eight case subjects.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

  • Received July 8, 2005.
  • Accepted September 17, 2005.
  • DIABETES CARE

References

  1. ↵
    Ryan EA, Lakey JRT, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AMJ: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 51:2148–2157, 2002
    OpenUrlAbstract/FREE Full Text
  2. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsuomo I, Ihm S-H, Zhang HJ, Parkey J, Hunter DW, Sutherland DER: Single donor, marginal dose islet transplantation in patients with type 1 diabetes. JAMA 293:830–835, 2005
    OpenUrlCrossRefPubMedWeb of Science
  3. Goss JA, Goodpastor SE, Brunicardi FC, Soltes GD, Garber AJ, Hamilton DJ, Alejandro R, Ricordi C: Development of a human pancreatic islet transplant program through a collaborative relationship with a remote islet isolation center. Transplantation 77:462–466, 2004
    OpenUrlCrossRefPubMedWeb of Science
  4. Kessler L, Bucher P, Milliat-Guittard L, Benhamou PY, Soltes GD, Garber AJ, Badeet L, Thivelet C, Bayle F, Oberholzer J, Renoult E, Brun MJ, Rifle G, Atlan C, Colin C, Morel P, GRAGIL Group: Influence of islet transportation on pancreatic islet transplantation in type 1 diabetic patients with the Swiss-French network. Transplantation 77:1301–1304, 2004
    OpenUrlCrossRefPubMed
  5. ↵
    Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JRT, Shapiro AMJ: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069, 2005
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Calafiore R, Basta G, Luca G, Calvitti M, Calabrese G, Racanicchi L, Macchiarulo G, Mancuso F, Guido L, Brunetti P: Grafts of microencapsulated pancreatic islet cells for the therapy of diabetes mellitus in nonimmunosuppressed animals. Biotechnol Applied Biochem 39:159–164, 2004
    OpenUrlCrossRef
  7. ↵
    Basta G, Sarchielli P, Luca G, Rcanicchi L, Nastruzzi C, Guido L, Mancuso F, Macchiarulo G, Calabrese G, Brunetti P, Calafiore R: Optimized parameters for microencapsulation of pancreatic islet cells: an in vitro study clueing on islet graft immunoprotection in type 1 diabetes mellitus. Transpl Immunol 13:289–296, 2004
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 29 (1)

In this Issue

January 2006, 29(1)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes
Riccardo Calafiore, Giuseppe Basta, Giovanni Luca, Angelo Lemmi, M. Pia Montanucci, Giuseppe Calabrese, Leda Racanicchi, Francesca Mancuso, Paolo Brunetti
Diabetes Care Jan 2006, 29 (1) 137-138; DOI: 10.2337/diacare.29.01.06.dc05-1270

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes
Riccardo Calafiore, Giuseppe Basta, Giovanni Luca, Angelo Lemmi, M. Pia Montanucci, Giuseppe Calabrese, Leda Racanicchi, Francesca Mancuso, Paolo Brunetti
Diabetes Care Jan 2006, 29 (1) 137-138; DOI: 10.2337/diacare.29.01.06.dc05-1270
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide
  • Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
  • Diabetes Antibody Standardization Program
Show more Emerging Treatments and Technologies

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.